• Recruiting

NCT05393804: Phase 2: Trial of CART Ide-cel (bb2121) Status Post Hematopoietic cell Transplantation

NCT05393804: Phase 2: A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant


cart-ide-cel-bb2121-mskcc

The purpose of this study is to see if the quality of T cells used to create ide-cel (bb2121) affects how ide-cel prevents cancer from coming back in people with relapsed or refractory multiple myeloma (MM), and who have had a hematopoietic cell transplant.


Sponsor

Memorial Sloan Kettering Cancer Center

 

ClinicalTrials.gov Identifier: NCT05393804


Official Title: Feasibility Trial of Autologous Anti-B Cell Maturation Antigen Chimeric Antigen Receptor T Cell Therapy Using Ide-Cel for Multiple Myeloma Patients Status Post Hematopoietic Cell Transplantation

First Posted: May 26, 2022


Click here for details on ClinicalTrials.gov

 

CART - BCMA : National Cancer Institute


Idecabtagene Vicleucel : National Cancer Institute

Idecabtagene Vicleucel : MedlinePlus Drug Information

Anti-BCMA CAR T Cells BB2121

anti-BCMA-CAR-transduced T cells BB2121

BCMA-specific CAR-expressing T lymphocytes BB2121

ide-cel

Abecma

BB2121

 

Biological: Ide-cel (bb2121)

 

Location

United States, New York

Posts Archive